Harmony Biosciences Stock Declines Over 5 % After Leadership Change Announcement

Harmony Biosciences Stock Declines Over 5 % After Leadership Change Announcement

THE MONEYWISE JOURNAL  ·  finance  ·  Tuesday, October 13, 2026
Harmony Biosciences Stock Declines Over 5 % After Leadership Change Announcement

The announcement triggered a sharp sell‑off, sending the stock down more than 5 % on Monday.

By MoneyWise Guide

Harmony Biosciences announced a planned succession in its C‑suite that morning, naming COO Peter Anastasiou as the incoming CEO effective January 1, 2027. The announcement triggered a sharp sell‑off, sending the stock down more than 5 % on Monday.

Key Takeaways

  • Peter Anastasiou will become CEO on Jan. 1, 2027.
  • Jeffrey Dayno will transition to an advisory role through 2027.
  • The stock fell more than 5 % after the announcement.
  • Full‑year net‑revenue guidance for Wakix is $1 billion to $1.04 billion.
Metric Value Why it matters
Leadership transition Peter Anastasiou named CEO effective Jan. 1, 2027 Signals continuity and a planned succession plan
Stock performance >5 % decline on Monday Immediate market reaction to leadership news
Revenue outlook $1 billion to $1.04 billion for Wakix Guides future earnings expectations
Effective date Jan. 1, 2027 Marks the transition point for new leadership

Leadership Transition Details

The announcement, released that morning, identified Peter Anastasiou—currently COO and a board member—as the next CEO. Jeffrey Dayno, the current chief executive, will move to an advisory role that will last through 2027. This change is part of a planned succession strategy to replace the outgoing CEO with the COO.

Impact on the Stock

Investors reacted swiftly, selling shares eagerly and causing the stock to decline more than 5 % on Monday. The sell‑off reflects market sensitivity to executive changes, even when the transition is pre‑planned.

Product and Revenue Outlook

Harmony Biosciences’ flagship drug, Wakix (pitolisant), is approved by the U.S. Food and Drug Administration for certain sleep disorders. The company has guided full‑year net revenue for Wakix at $1 billion to $1.04 billion, providing a benchmark for future earnings.

Investor Reaction

The press release included the phrase “steady as she goes,” indicating the company’s confidence in the transition. However, the immediate market response was a sharp decline, showing that investors weigh leadership changes heavily when assessing company value.

Background on Wakix

Wakix, the brand name for pitolisant, has received FDA approval for treating certain sleep disorders. Jeffrey Dayno had previously served as chief medical officer during the drug’s development, underscoring his deep involvement in the product’s success.

Why It Matters

For investors, the leadership shift signals a potential change in strategic direction, even if the transition is orderly. The >5 % stock drop highlights how executive news can influence market sentiment. The revenue guidance for Wakix provides a concrete metric for evaluating the company’s financial trajectory.

Frequently Asked Questions

Who is taking over as CEO of Harmony Biosciences?

Peter Anastasiou, the current COO and a board member, will become CEO effective January 1, 2027.

When does the leadership transition take effect?

The new CEO will assume the role on January 1, 2027.

Why did the stock fall more than 5 %?

Investors sold shares eagerly after the announcement of the leadership change, causing the sharp decline.

What is the revenue guidance for Wakix?

Harmony Biosciences expects full‑year net revenue for Wakix to be between $1 billion and $1.04 billion.

What is Wakix and its regulatory status?

Wakix, the brand name for pitolisant, is approved by the U.S. Food and Drug Administration for certain sleep disorders.

Bottom Line

Harmony Biosciences’ planned succession, naming COO Peter Anastasiou as CEO effective 2027, triggered a >5 % stock decline on Monday. While the company maintains a solid revenue outlook for its FDA‑approved drug Wakix, the market’s immediate reaction underscores the sensitivity of investors to executive changes.

This is educational information, not personalized financial advice.

Reporting based on: original source.